CVS CVS Health Corp
Company Analysis
Latest News
Thyme Care doubles valuation to $2B, expanding into biosimilars and trials
Thyme Care secured $125 million in a Series E funding round. The investment values the virtual cancer care platform at more than $2 billion. This valuation...
Robert Olstein's firm liquidates its entire stake in CVS Health
In a quarterly disclosure filed with the SEC, major investor Robert Olstein of Olstein Capital Management revealed the complete liquidation of his firm's...
Viking Global Takes New $379 Million Position in CVS Health
Andreas Halvorsen's Viking Global Investors initiated a new stake in CVS Health Corp. during the second quarter of 2026, according to a recent SEC disclosure....
CVS Health Appoints JPMorgan Chase Data Executive to Board, Announces Director Resignation
CVS Health announced changes to its Board of Directors, appointing Teresa Heitsenrether, EVP and Chief Data & Analytics Officer of JPMorgan Chase. The company...
CVS Beats Expectations and Raises Its Outlook, So Why Are Investors Dumping the Stock?
Shares of CVS Health plunged roughly 10% in pre-market trading to $93.97 on August 7, despite the company posting a second-quarter earnings and revenue beat...
🔴 CVS Health is trading 8.1% down today as early post-earnings gains evaporate
CVS Health is trading 8.1% down now at $95.97 as early gains from strong Q2 2026 results and raised full-year guidance evaporate. • The stock initially surged...
🔴 CVS Health is trading 10% down today despite Q2 beat and raised 2026 guidance
CVS Health is trading 10% down at $93.97 as investors focus on long-term insurance and cost concerns despite the company reporting a second-quarter earnings...
CVS Health's second quarter revenue and EPS beat estimates, prompting a raised full-year 2026 outlook.
CVS Health reported second quarter 2026 revenues of $106.1 billion, up 7.3% year-over-year, and an Adjusted EPS of $2.58. The results surpassed analyst...
CVS Health Corp Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
CVS Health is projected to report Q2 2026 revenue of $100.09 billion and EPS of $1.87, with shares currently trading at $104.43 against a mean analyst price...
CVS Health warns GLP-1 drugs lack ROI, citing high monthly costs
CVS Health CEO David Joyner told the Washington Post that broad insurance coverage for GLP-1 weight-loss drugs remains economically unfeasible for...
🟢 CVS Health Corp is trading 4.3% up today on GLP-1 program expansion and BofA price target hike
• BofA Securities has raised its price target on CVS Health to $110 from $100, maintaining a Buy rating. • The upgrade follows CVS Health's announcement of...
CVS Health Eyes 20% Upside, UBS Hikes Price on Earnings Optimism
UBS Group raised its price objective for CVS Health to $115.00 from $100.00. The investment bank maintained its buy rating on the stock. The new target...
CVS Health Sued for $250 Million Over Alleged Drug Pricing Scheme
Mount Sinai Health System, Michigan Medicine, and the University of Kansas Health System filed federal lawsuits against CVS Health. The complaints accuse CVS...
CVS Health's first quarter 2026 results beat estimates with revenue up 6.2%, leading to raised full-year guidance.
CVS Health reported first quarter 2026 revenues of $100.4 billion, a 6.2% year-over-year increase, and an Adjusted EPS of $2.57. The strong performance...
CVS Health Corp Q1 2026 Earnings Preview: What Analysts Expect on May 06, 2026
For the first quarter of 2026, analysts expect CVS Health to report consensus revenue of approximately $94.37 billion and adjusted EPS of $2.21, as the stock...
CVS’s Aetna to Pay $117.7 Million Over Alleged Medicare Risk Adjustment Overcharges
CVS Health’s Aetna unit will pay $117.7 million to resolve allegations that it violated the False Claims Act. The U.S. Department of Justice claimed the...